Palisade Bio and Newsoara Receive NMPA Clearance to Commence Phase 3 Clinical Trial in China Evaluating LB1148 to Accelerate the Return of Bowel Function Following Abdominal Surgery

Palisade Bio and Newsoara Biopharma Co. Ltd announced they have received clearance from the National Medical Products Administration in China to proceed with their Phase III clinical trial to evaluate LB1148 for accelerated return of bowel function in adult patients undergoing bowel/abdominal surgery.
[Palisade Bio (GlobeNewswire, Inc.)]
Press Release
spot_img

Stay up-to-date with your field!

Subscribe for free weekly science newsletters.

Related News